An ongoing clinical trial (NCT05177796) is evaluating the enhancement of immunotherapy by targeting the EGFR pathway with panitumumab and pembrolizumab in combination with neoadjuvant chemotherapy in TN-IBC. Here, EGFR is linked to inflammatory breast carcinoma.